Live Breaking News & Updates on நோயாளிகள் அப்பால்

Stay updated with breaking news from நோயாளிகள் அப்பால். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Antengene and Its Partners Publish Preclinical Data Demonstrating the Encouraging Activity of Selinexor in the Prevention and Treatment of SARS-CoV-2 Infections


Share this article
Share this article
SHANGHAI and HONG KONG, July 25, 2021 /PRNewswire/ In June 2021, results from a preclinical study jointly conducted by Antengene, American biopharmaceutical company Karyopharm Therapeutics and University of Georgia College of Veterinary Medicine has been published in a paper titled
selinexor, a novel selective inhibitor of nuclear export, reduces SARS-CoV-2 infection and protects the respiratory system in vivo , in
Antiviral Research (192(2021),105-115), a leading scientific journal in the field of virology. Results from the study showed that the nuclear export protein exportin-1 (XPO1) plays a direct role in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and the pathogenesis of coronavirus disease 19 (COVID-19); and the selective oral inhibitor of XPO1, selinexor, has potent anti-SARS-CoV-2 activity both in vitro and in vivo. These results demonstrated selinexor as a potential therapeutic strate ....

Landesmany Selinexor , Asia Pacific , Antengene Corporation , Antengene Corporation Limited , Corporation Limited , Asia Pacific Region , Patients Beyond , ஆசியா பெஸிஃபிக் , நிறுவனம் வரையறுக்கப்பட்டவை , ஆசியா பெஸிஃபிக் பகுதி , நோயாளிகள் அப்பால் ,

International hospital accreditation skyrockets 1,000%


International hospital accreditation skyrockets 1,000%
August 18, 2009
In the last five years, the number of JCI (Joint Commission International) accredited public and private hospitals around the world has increased by nearly 1,000 percent.
In the last five years, the number of JCI (Joint Commission International) accredited public and private hospitals around the world has increased by nearly 1,000 percent. Up from a mere 27 hospitals and health care organizations with that accreditation in 2004, currently over 250 such entities in 36 countries have now been accredited by the JCI. This extremely high standard of “American accreditation” now instills a new level of confidence in US citizens seeking affordable health care alternatives abroad. With the US Congress currently locked in a fierce battle over how to solve the national health care crisis, Josef Woodman, author of Patients Beyond Borders, joins Sandy Dhuyvetter on TravelTalkRADIO to discuss this extraordin ....

Kuala Lumpur , Slovak Republic , United States , United Kingdom , Saudi Arabia , Joe Woodman , Josef Woodman , Sandy Dhuyvetter , Johns Hopkins , Ambassadors Club At Narita , Duke Medical Center , Malaysia Society For Quality Healthcare , Prince Court Medical Center , Commission International , Us Congress , Joint Commission International , Patients Beyond Borders , Patients Beyond , Ambassadors Club , Mayo Clinic , Duke Medical , Good Housekeeping Seal , Latin America , Middle East , Middle Easterners , Petronas Towers ,

Antengene Submits New Drug Application for Selinexor in Taiwan for the Treatment of Three Indications in Hematologic Malignancies


Antengene Submits New Drug Application for Selinexor in Taiwan for the Treatment of Three Indications in Hematologic Malignancies
-In July 2019, selinexor (XPOVIO®) was approved by the U.S. FDA and became the first and only XPO1 inhibitor indicated for the treatment of hematologic malignancies.
-Selinexor has been approved in the U.S., Israel, UK, and EU countries.
News provided by
Share this article
Share this article
SHANGHAI and HONG KONG, July 13, 2021 /PRNewswire/ Antengene Corporation Limited ( Antengene , SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has submitted a New Drug Application (NDA) to the Taiwan Food and Drug Administration (TFDA) for selinexor, a first-in-class XPO1 inhibitor, for three indications: in combination with bortezomib and dexamethasone (XVd) ....

New Zealand , South Korea , Kevin Lynch , Jay Mei , Asia Pacific , Karyopharm Therapeutics Inc , Antengene Corporation , European Commission , Drug Administration , China National Medical Products Administration , Prnewswire Antengene Corporation Limited , Antengene Corporation Limited , Connective Tissue Oncology Society , Israeli Ministry Of Health , Ministry Of Food , Corporation Limited , New Drug Application , Taiwan Food , New Drug Applications , Priority Review , National Medical Products Administration , Orphan Drug Designation , Drug Safety , Chief Medical Officer , Karyopharm Therapeutics , Greater China ,